Department of Medicine, Srinivasa Diabetic Research Centre, Bangalore 560 050, India.
Evid Based Complement Alternat Med. 2012;2012:216970. doi: 10.1155/2012/216970. Epub 2011 Jun 16.
A randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy of GutGard, an extract of Glycyrrhiza glabra, in patients with functional dyspepsia. The primary outcome variables of the study were the change in the severity symptoms and the global assessment of efficacy. The quality of life was evaluated as a secondary outcome measure. The patients received either placebo or GutGard (75 mg twice daily) for 30 days. Efficacy was evaluated in terms of change in the severity of symptoms (as measured by 7-point Likert scale), the global assessment of efficacy, and the assessment of quality of life using the short-form Nepean Dyspepsia Index. In comparison with placebo, GutGard showed a significant decrease (P ≤ .05) in total symptom scores on day 15 and day 30, respectively. Similarly, GutGard showed marked improvement in the global assessment of efficacy in comparison to the placebo. The GutGard group also showed a significant decrease (P ≤ .05) in the Nepean dyspepsia index on day 15 and 30, respectively, when compared to placebo. GutGard was generally found to be safe and well-tolerated by all patients. GutGard has shown significant efficacy in the management of functional dyspepsia.
一项随机、双盲、安慰剂对照研究评估了甘草提取物 GutGard 治疗功能性消化不良的疗效。该研究的主要疗效变量是症状严重程度的变化和整体疗效评估。生活质量作为次要疗效评估指标。患者接受安慰剂或 GutGard(每天 2 次,每次 75 毫克)治疗 30 天。疗效通过症状严重程度的变化(通过 7 点 Likert 量表评估)、整体疗效评估和使用短版 Nepean 消化不良指数评估生活质量来评估。与安慰剂相比,GutGard 在第 15 天和第 30 天分别显著降低了总症状评分(P ≤.05)。同样,与安慰剂相比,GutGard 在整体疗效评估方面显示出明显改善。与安慰剂相比,GutGard 组在第 15 天和第 30 天的 Nepean 消化不良指数也分别显著降低(P ≤.05)。GutGard 被发现对所有患者均安全且耐受良好。GutGard 对功能性消化不良的治疗具有显著疗效。